In 2002, Amylin had entered into an alliance with Lilly for the global development and commercialization of exenatide, a medicine indicated as a first line treatment for type 2 diabetes that is currently marketed as BYETTA (exenatide) injection.
The US District Court restrained Lilly from proceeding with its plans to use the same sales force to sell both exenatide and Boehringer Ingelheim competitive linagliptin.
The court also enjoined Lilly from disclosing any confidential information about exenatide to any of its sales representatives or employees participating in the marketing, promotion or sale of linagliptin.
BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
Amylin Pharmaceuticals also developes medicines for diabetes like SYMLIN (pramlintide acetate) injection.